Table 4.
Correlation analyses between anthropometric and biochemical variables associated to MetS with some of the DNA methylation at the CpG islands (CpGi) analyzed. Only CpG that presented any significant association are represented.
| MetS Index | BMI | Waist | Glucose | Tg | HDL-c | LDL-c | SBP | DBP | HOMA-IR | |
|---|---|---|---|---|---|---|---|---|---|---|
| PPARA P2 | 0.276 * | 0.076 | 0.165 | 0.166 | 0.392 ** | 0.061 | 0.08 | 0.066 | −0.025 | 0.229 * |
| PPARG P1 | −0.072 | 0.306 * | 0.169 | −0.224 | −0.194 | 0.015 | −0.197 | −0.2 | −0.293 * | −0.058 |
| PPARG P3 | −0.078 | 0.138 | 0.174 | 0.03 | −0.139 | 0.021 | −0.218 | 0.037 | −0.283 * | 0.112 |
| RXRA P1 | −0.102 | −0.298 ** | −0.229 * | −0.052 | 0.025 | −0.095 | 0.127 | −0.066 | −0.225 | −0.032 |
| SREBF2 P2 | 0.056 | 0.006 | 0.144 | 0.112 | 0.136 | −0.032 | 0.189 | −0.224 | −0.262 * | 0.121 |
| LRP1 P2 | 0.09 | −0.065 | −0.048 | 0.114 | −0.215 | 0.373 * | −0.055 | 0.192 | 0.180 | 0.251 |
| LPL P3 | 0.135 | 0.029 | 0.089 | 0.128 | 0.245 * | −0.102 | 0.085 | 0.126 | −0.111 | 0.149 |
| SCD P3 | −0.056 | −0.340 * | −0.283 | −0.096 | −0.018 | 0.108 | 0.22 | 0.087 | −0.117 | −0.03 |
| SCD P6 | −0.325 * | −0.116 | −0.17 | −0.141 | −0.134 | 0.121 | 0.102 | −0.275 | −0.232 | −0.172 |
| TNF P1 | −0.212 | 0.132 | 0.046 | −0.034 | −0.188 | 0.283 * | −0.02 | −0.010 | −0.115 | 0.029 |
| TNF P2 | −0.420 ** | 0.054 | −0.061 | −0.192 | −0.273 * | 0.304 * | −0.195 | −0.188 | −0.217 | −0.196 |
| TNF P3 | −0.320 * | 0.151 | −0.021 | −0.094 | −0.155 | 0.222 | −0.109 | −0.237 | −0.242 | −0.03 |
| TNF P4 | −0.330 * | −0.006 | −0.096 | −0.278 * | −0.203 | 0.098 | −0.295 * | −0.245 | −0.305 * | −0.133 |
| TNF P5 | −0.281 * | 0.132 | −0.100 | −0.153 | −0.281 * | 0.380 ** | −0.132 | −0.097 | −0.008 | −0.074 |
| LEP P1 | 0.088 | 0.081 | −0.159 | 0.061 | −0.071 | 0.015 | 0.229 * | 0.264 * | 0.230 * | 0.028 |
Number of metabolic syndrome variables present in the subject of study (MetS index); body mass index (BMI); Triglycerides (TG); high-density lipoprotein cholesterol (HDL-c); low-density lipoprotein cholesterol (LDL-c); systolic blood pressure (SBP); diastolic blood pressure (DBP); homeostatic model assessment of insulin resistance (HOMA-IR); peroxisome proliferator-activated receptor alpha DNA methylation at position 2 (PPARA P2); retinoid X receptor alpha methylation at position 1 (RXRA P1); leptin DNA methylation at position 1 (LEP P1); sterol regulatory element binding transcription factor DNA methylation at position 2 (SREBF2 P2); Stearoyl-CoA desaturase DNA methylation at positions 3 and 6 (SCD P3 and P6); Tumor necrosis factor DNA methylation at positions P1 to P5 (TNF P1–P5); peroxisome proliferator-activated receptor gamma DNA methylation at positions 1and 2 (PPARG P1 and P2); Lipoprotein lipase DNA methylation at position 3 (LPL P3); Low-density lipoprotein receptor-related protein 1 DNA methylation at position 2 (LRP1 P2). * and ** means p < 0.05 and p < 0.01 respectively.